Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report

Plasma cell leukemia (PCL) is an aggressive and high-risk variant of multiple myeloma (MM) with a very poor prognosis. Given its rarity and aggressiveness, there is a lack of clinical trials testing the efficacity of novel therapies in these patients. New immune approaches such as B-cell maturation...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2024-11, Vol.15, p.1495233
Main Authors: Bernardi, Chiara, Beauverd, Yan, Tran, Thien An, Maulini, Marie, Mappoura, Maria, Morin, Sarah, Simonetta, Federico, Cairoli, Anne, Auner, Holger W, Samii, Kaveh, Chalandon, Yves, de Ramon Ortiz, Carmen
Format: Article
Language:English
Subjects:
Antibodies, Bispecific - therapeutic use
Antineoplastic Agents, Immunological - therapeutic use
B-Cell Maturation Antigen - antagonists & inhibitors
B-Cell Maturation Antigen - immunology
BCMA
bispecific Ab
elranatamab
GPRC5D
Humans
Leukemia, Plasma Cell - drug therapy
Leukemia, Plasma Cell - immunology
Leukemia, Plasma Cell - therapy
Male
Middle Aged
plasma cell leukemia (PCL)
Receptors, G-Protein-Coupled - immunology
talquetamab
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Plasma cell leukemia (PCL) is an aggressive and high-risk variant of multiple myeloma (MM) with a very poor prognosis. Given its rarity and aggressiveness, there is a lack of clinical trials testing the efficacity of novel therapies in these patients. New immune approaches such as B-cell maturation antigen (BCMA) and G protein-coupled receptor, family C, group 5, member D (GPRC5D) -targeting agents, including chimeric antigen receptor (CAR) T-cells and bispecific antibodies could play a role in PCL treatment. However, PCL patients were excluded from recent pivotal clinical trials testing those agents and only some case reports have been published. We present here the clinical course of a patient with relapsed/refractory (R/R) primary (p) PCL who was treated with anti-BCMA and anti-GPRC5D bispecific antibodies at our center.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2024.1495233